Clinical trials: Heart Failure With Preserved Ejection Fraction (HFPEF)
Heart Failure With Preserved Ejection Fraction
The Relationship Between Epicardial Fat Tissue and Cardiac Function in HFpEF Patients
Heart failure with preserved ejection fraction (HFpEF) refers to a group of symptoms and signs of heart failure, normal or near-normal left ventricular systolic function (EF>50%), and ventricular muscle diastolic dysfunction and…
- Trial name
- NCT05068934
- Where
- China
- Volunteers
- 1,083 people
- Sponsor
- Dongying Zhang
Heart Failure With Preserved Ejection Fraction
Carvedilol SR Study for Biomarkers From Blood and Urine and Safety of in Patients With Heart Failure With Preserved Ejection Fraction
Beta blockers have been used to reduce the mortality and heart failure rehospitalization in heart failure with reduced ejection fraction (HFrEF) patients in addition to ACEI/ARB, MRA, ivabradine and ARNI.
- Trial name
- NCT03948685
- Testing
- Carvedilol SR
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Yonsei University
Cardiac Amyloidosis, Heart Failure With Preserved Ejection Fraction (HFPEF)
AI-based Echocardiography for Detection of Cardiac Amyloidosis
Cardiac amyloidosis is characterized by deposition of misfolded protein in the myocardium causing mainly heart failure symptoms with preserved left ventricular ejection fraction.
- Conditions
- Cardiac Amyloidosis, Heart Failure With Preserved Ejection Fraction (HFPEF), Left Ventricular Hypertrophy
- Trial name
- ORCHESTRA (NCT07529860)
- Testing
- AI-based echocardiogram
- Volunteers
- 200 people
- Sponsor
- Germans Trias i Pujol Hospital
Heart Failure With Preserved Ejection Fraction
Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF
This is a Phase 2A, randomized, parallel-group, placebo-controlled, double-blind, within subject dose escalation trial with 3 dose levels of HU6 and placebo. Subjects will be randomized (1:1) either to HU6 or placebo.
- Trial name
- HFpEF (NCT05284617)
- Testing
- HU6
- Where
- 15 sites in United States
- Volunteers
- 67 people
- Sponsor
- Rivus Pharmaceuticals, Inc.
Heart Failure With Normal Ejection Fraction
Renal Hemodynamics in Patients With HFpEF
Impaired renal function and heart failure with preserved ejection fraction (HFpEF) are two often co-existing medical conditions and are known to be associated with adverse cardiovascular outcome and increased mortality.
- Trial name
- NCT03672591
- Testing
- Renal clearance examination
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Heart Failure, Diastolic (HFpEF)
Pogejiuxin Decoction Combination of Conventional Western Medicine for the Treatment of Heart Failure With Preserved Ejection Fraction
The objective of this study is to investigate the potential of Pogejiuxin Decoction to enhance the efficacy and mitigate the adverse effects associated with conventional treatment in patients with heart failure and preserved…
- Trial name
- NCT06629246
- Testing
- Conventional heart failure treatment, Pogejiuxin decoction combined with conventional heart failure treatment
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chongqing Traditional Chinese Medicine Hospital
Iron-deficiency, Heart Failure
Effect of IV Iron in Patients With Heart Failure With Preserved Ejection Fraction
This study addresses, whether treatment with IV iron for patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency (ID), both with or without anaemia, can improve exercise capacity as measured by…
- Trial name
- FAIR-HFpEF (NCT03074591)
- Testing
- Ferric Carboxymaltose 50Mg/Ml Inj 15Ml, Saline Solution for Injection
- Where
- 7 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Charite University, Berlin, Germany
Heart Failure With Preserved Ejection Fraction (HFpEF)
A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers
This is an open-label, non-randomized, fixed sequence study conducted at a single study center with primary aim to assess the pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with…
- Trial name
- NCT03843060
- Testing
- AZD9977, Itraconazole
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Heart Failure With Preserved Ejection Fraction (HFPEF)
Association of Heterogeneous Circulating Biomarkers and Anamnestic Factors of Pregnancy Adverse Course and Outcomes With the Prognosis of Heart Failure With Preserved Ejection Fraction
The primary purpose of this study is to evaluate possible association of some heterogeneous circulating biomarkers and anamnestic factors of pregnancy adverse course and outcomes with the prognosis of heart failure with preserved…
- Trial name
- CARPO-HF (NCT06803849)
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Heart Failure With Preserved Ejection Fraction, Heart Failure, Diastolic
Multiple-biomarker Approach for Individualized Treatment of Heart Failure With Preserved Ejection Fraction
The primary objective is to investigate the association between temporal evolutions of blood biomarkers and clinical adverse events, in order to produce a dynamic, individual, and accurate prediction model for patients with…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Heart Failure, Diastolic, Chronic Heart Failure
- Trial name
- ADAPT-HFpEF (NCT06785506)
- Where
- 6 sites in Netherlands
- Volunteers
- 200 people
- Sponsor
- Erasmus Medical Center
Heart Failure
Effect of Finerenone on Myocardial Fibrosis and Cardiac Function in HFmrEF/HFpEF Patients
FINE-FOCUS study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of Finerenone versus placebo on myocardial fibrosis and cardiac structure/function as assessed by…
- Trial name
- FINE-FOCUS (NCT07583173)
- Testing
- Oral finerenone
- Where
- China
- Volunteers
- 104 people
- Sponsor
- China National Center for Cardiovascular Diseases
Valvular Heart Disease Stenosis and Regurgitation (Diagnosis), Pulmonary Hypertension (Diagnosis)
Prospective Evaluation of AI-ECG for SHD Detection
AI-ECG-SHD is a multicentre prospective observational diagnostic accuracy study evaluating artificial intelligence-enhanced electrocardiography (AI-ECG) for the detection of structural heart disease in adults undergoing…
- Conditions
- Valvular Heart Disease Stenosis and Regurgitation (Diagnosis), Pulmonary Hypertension (Diagnosis), Heart Failure With Reduced Ejection Fraction (HFrEF; Diagnosis), Heart Failure With Preserved Ejection Fraction (HFpEF; Diagnosis)
- Trial name
- AI-ECG-SHD (NCT07057466)
- Testing
- Traditional 12-lead Electrocardiogram, Apple Watch Series 4 Single-lead Electrocardiogram, Eko Core 500 Digital Stethoscope 3-lead Electrocardiogram
- Where
- 6 sites in United Kingdom
- Volunteers
- 590 people
- Sponsor
- Imperial College London
Hypertension (HTN), Heart Failure With Preserved Ejection Fraction (HFpEF
Clinical Feasibility of Cardiac Neuromodulation Therapy for Heart Failure With Preserved Ejection Fraction
This is an open-label pilot study to evaluate the feasibility of Cardiac Neuromodulation Therapy (CNT) in patients with high blood pressure and heart failure who require dual-chamber pacemaker implantation or replacement.
- Conditions
- Hypertension (HTN), Heart Failure With Preserved Ejection Fraction (HFpEF, Hypertension, Systolic
- Trial name
- NCT07598760
- Testing
- Moderato Plus device with Cardiac Neuromodulation Therapy
- Where
- 2 sites in Georgia
- Volunteers
- 20 people
- Sponsor
- BackBeat Medical Inc
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction
This was a multicenter, randomized (1:1; oral treprostinil to placebo), double-blind, placebo-controlled study in subjects with World Health Organization (WHO) Group 2 pulmonary hypertension (PH) associated with heart failure…
- Trial name
- NCT03037580
- Testing
- Oral treprostinil
- Where
- 82 sites in United States
- Volunteers
- 84 people
- Sponsor
- United Therapeutics
Heart Failure With Preserved Ejection Fraction (HFPEF)
CAPTURE-HFpEF: National Study of Identification and Phenotyping of Heart Failure With Preserved Ejection Fraction
The goal of this observational study is to improve early detection, characterization, and understanding of heart failure with preserved ejection fraction (HFpEF) in adults at risk of or diagnosed with HFpEF, including men and…
- Trial name
- CAPTURE-HFpEF (NCT07493590)
- Testing
- HFpEF Observational Measurements
- Where
- Denmark
- Volunteers
- 30,000 people
- Sponsor
- Herlev and Gentofte Hospital
Cardiac Amyloidosis, Heart Failure With Preserved Ejection Fraction
Cardiac Amyloidosis in HFpEF Tunisian Patients
Cardiac amyloidosis (CA) has recently been reported as a common cause of heart failure with preserved left ventricular ejection fraction (HFpEF), with a prevalence of 6% in elderly HFpEF patients.
- Conditions
- Cardiac Amyloidosis, Heart Failure With Preserved Ejection Fraction, Echocardiography, CMR
- Trial name
- Amy-Card (NCT06201832)
- Where
- Tunisia
- Volunteers
- 87 people
- Sponsor
- University Tunis El Manar
Heart Failure
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.
The primary objective of the study is to evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6 minute walk test (6MWT) in patients with chronic heart failure (CHF) with preserved ejection…
- Trial name
- NCT03448406
- Testing
- Empagliflozin
- Where
- 108 sites in United States, Australia and 9 more
- Volunteers
- 315 people
- Sponsor
- Boehringer Ingelheim
HFpEF - Heart Failure With Preserved Ejection Fraction
The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)
This study will evaluate the effect of 12 weeks of treatment with tamibarotene compared with placebo on N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients with heart failure with preserved ejection fraction…
- Trial name
- RELIEF (NCT07855692)
- Testing
- Tamibarotene
- Where
- 4 sites in Japan
- Volunteers
- 90 people
- Sponsor
- Nagoya University
Heart Failure
REALIsM-HF Pilot Study
The study aims to explore two marketed devices providing a multimarker monitoring including physical activity under real-life conditions in patients with heart failure with preserved ejection fraction (HFpEF) and with heart…
- Trial name
- REALIsM-HF (NCT03507439)
- Testing
- AVIVO Mobile Patient Management (MPM) System, VitalPatch biosensor, DynaPort Move Monitor
- Where
- 5 sites in United States, Germany and 1 more
- Volunteers
- 27 people
- Sponsor
- Bayer
Heart Failure, Diastolic
Mechanisms of Right Ventricular Adaptation in Patients With Heart Failure With Preserved Ejection Fraction
Biventricular PV-loop studies and advanced imaging to assess left-to-right ventricular interaction in HFpEF: In a group of 30 HFpEF patients with clinical indication for LH/RH catheter investigation, we will perform biventricular…
- Trial name
- INTERACT-HFpEF (NCT04154657)
- Testing
- conductance catheter measurement
- Where
- 2 sites in Germany
- Volunteers
- 30 people
- Sponsor
- Johann Wolfgang Goethe University Hospital